Novel combination therapy could reduce leukemia relapse rate, extending window for bone marrow transplants

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong ...

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AMLCAMBRIDGE, ...
Labroots

Acute Myeloid Leukemia Patients Inform Adoptive Cell Therapy

A limitation to cancer treatment, specifically acute myeloid leukemia (AML) is the ability to effectively target tumors cells ...
Verywell Health on MSN

How leukemia is treated

Medically reviewed by Douglas A. Nelson, MD The treatment for leukemia depends on many factors, including the type, subtype, and stage of the disease, and a person’s age and general health. Treatment ...
ascopubs.org

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...